Joint statement in response to NICE’s decision to approve anti-GD2 antibody therapy dinutuximab beta
Families now know their very sick child will be able to have the best treatment that gives the greatest chance of long-term survival here in the UK.
Anti-GD2 antibody therapy update, May 2018
Following the recent provisional decision by the National Institute for Health and Care Excellence (NICE) not to approve dinutuximab beta (Qarziba™) for use on the NHS in England and Wales, we have updated our briefing document.
Joint statement in response to NICE’s preliminary decision on Anti-GD2 antibody therapy dinutuximab beta
From Solving Kids’ Cancer, Neuroblastoma UK, the Children’s Cancer and Leukaemia group, JACK, The Bradley Lowery Foundation, Hugs from Henry, Christopher’s Smile, Niamh’s Next Steps and Smile with Siddy.
Anti-GD2 antibody therapy update, March 2018
A NICE committee hearing will be held on 11th April to discuss whether or not to recommend dinutuximab beta antibody therapy for NHS use. An application has been received from pharmaceutical company EUSA Pharma (who hold the European and UK licence).
New partnership to help families travelling abroad for treatment
We’re delighted to let you know that we’re now working with the St George’s Society of New York who will provide a helping hand for families whose children are having therapies such as immunotherapy clinical trials.
Anti-GD2 antibody therapy update, December 2017
In the UK, the first meeting of the National Institute for Health and Care Excellence (NICE) to appraise dinutuximab beta was held on 23rd November in Manchester.
GamesAid donates £69,729 for children with neuroblastoma
We are delighted to announce another significant award from GamesAid – a charity which supports children’s charities in the UK.
Anti-GD2 antibody therapy update, March 2017
Solving Kids’ Cancer has been working since 2015 to ensure continued availability of, and access to, antibody therapy.
Update on our appeal to NICE regarding dinutuximab
Following the announcement that the National Institute of Health and Care Excellence had refused to fund dinutuximab for UK children with neuroblastoma, we lodged an appeal against the decision on Friday July 29th 2016.
